PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

Completed

Conditions studied: Melanoma

In brief

Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.

Key facts

Study ID

NCT02492815

Run by

Bristol-Myers Squibb

People needed

1773

Starts

2013-10-31

Expected to finish

2016-04-30

Last updated by the study team

2019-01-30

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients have been enrolled in the EAPs
• Patients still alive must provide informed consent if required by local regulations
• Deceased patients are eligible per local regulations, their legal representatives must provide informed consent if required by local regulations

You may not qualify if…

• There are no specific exclusion criteria in this observational study other than the exclusion criteria of the EAP

Where it is running

• Local Institution — Boston, Massachusetts, United States
• Outcome Sciences Inc Dba Outcome — Boston, Massachusetts, United States
• Local Institution — Linz, Austria
• Local Institution — Brussels, Belgium
• Local Institution — Prague, Czechia
• Local Institution — Odense C, Denmark
• Local Institution — Rouen, France
• Elbe Klinikum Buxtehude — Buxtehude, Germany
• Local Institution — Debrecen, Hungary
• Local Institution — Dublin, Ireland
• Local Institution — Naples, Italy
• Local Institution — Amsterdam, Netherlands
• Local Institution — Oslo, Norway
• Local Institution — Moscow, Russia
• Local Institution — Valencia, Spain
• Local Institution — Zurich, Switzerland
• Local Institution — Guildford, Surrey, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.